Literature DB >> 17555420

Comparisons of the distribution of oesophageal acid exposure throughout the sleep period among the different gastro-oesophageal reflux disease groups.

R Dickman1, S Parthasarathy, I B Malagon, P Jones, B Han, J Powers, R Fass.   

Abstract

BACKGROUND: Nocturnal gastro-oesophageal reflux diseases (GERD) can lead to oesophageal mucosal injury and extra-oesophageal complications. AIM: To compare distribution of oesophageal acid exposure during sleep time among patients with non-erosive reflux disease and abnormal pH test (NERD-positive), erosive oesophagitis (EO) and Barrett's oesophagus (BO).
METHODS: Patients underwent endoscopy followed by 24-h oesophageal pH testing. Oesophageal acid exposure was assessed every 2 h of the sleep period (0-2, 2-4, 4-6 and 6-8 h). Each period of 2 h was evaluated for acid reflux parameters. All groups were matched by age, time from last meal and duration of sleep time.
RESULTS: Thirty-eight patients were enrolled (NERD-positive, 16; EO, 1.4; and BO, 8). All GERD groups demonstrated higher oesophageal acid exposure in the first vs. second half of the sleep period as determined by percent time pH <4 (BO: 34.7 vs.11.6, EO: 13.5 vs. 6.9, NERD-positive: 8.8 vs. 2.5, all P < 0.01). In general, patients with BO had a significantly higher distribution of oesophageal acid exposure than those with NERD-positive and EO.
CONCLUSIONS: Oesophageal acid exposure generally declines throughout the sleep period regardless of GERD group, but BO patients demonstrated the greatest decline during the sleep period.

Entities:  

Mesh:

Year:  2007        PMID: 17555420     DOI: 10.1111/j.1365-2036.2007.03347.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  12 in total

Review 1.  Gastroesophageal reflux disease and sleep disturbances.

Authors:  Yasuhiro Fujiwara; Tetsuo Arakawa; Ronnie Fass
Journal:  J Gastroenterol       Date:  2012-05-17       Impact factor: 7.527

Review 2.  The relationship between gastroesophageal reflux disease and sleep.

Authors:  Ronnie Fass
Journal:  Curr Gastroenterol Rep       Date:  2009-06

3.  GERD: GERD and insomnia-first degree relatives or distant cousins?

Authors:  Ellen Stein; Philip O Katz
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-01       Impact factor: 46.802

Review 4.  Advancements in the analysis of esophageal pH monitoring in GERD.

Authors:  Tiberiu Hershcovici; Anita Gasiorowska; Ronnie Fass
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-02       Impact factor: 46.802

5.  Poor sleep quality and obstructive sleep apnea in patients with GERD and Barrett's esophagus.

Authors:  M F Vela; J R Kramer; P A Richardson; R Dodge; H B El-Serag
Journal:  Neurogastroenterol Motil       Date:  2013-12-09       Impact factor: 3.598

6.  Gastroesophageal reflux disease and sleep disorders: evidence for a causal link and therapeutic implications.

Authors:  Hye-Kyung Jung; Rok Seon Choung; Nicholas J Talley
Journal:  J Neurogastroenterol Motil       Date:  2010-01-31       Impact factor: 4.924

7.  Nonerosive Reflux Disease (NERD) - An Update.

Authors:  Tiberiu Hershcovici; Ronnie Fass
Journal:  J Neurogastroenterol Motil       Date:  2010-01-31       Impact factor: 4.924

8.  Diagnosis and management of non-erosive reflux disease--the Vevey NERD Consensus Group.

Authors:  I M Modlin; R H Hunt; P Malfertheiner; P Moayyedi; E M Quigley; G N J Tytgat; J Tack; R C Heading; G Holtman; S F Moss
Journal:  Digestion       Date:  2009-06-17       Impact factor: 3.216

9.  Nocturnal gastroesophageal reflux revisited by impedance-pH monitoring.

Authors:  Fernando Fornari; Kathleen Blondeau; Veerle Mertens; Jan Tack; Daniel Sifrim
Journal:  J Neurogastroenterol Motil       Date:  2011-04-27       Impact factor: 4.924

10.  Barrett's esophagus and the risk of obstructive sleep apnea: a case-control study.

Authors:  Linda C Cummings; Ninad Shah; Santo Maimone; Wajeeh Salah; Vijay Khiani; Amitabh Chak
Journal:  BMC Gastroenterol       Date:  2013-05-11       Impact factor: 2.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.